| Dr Frederick Yosef Machado, PSYD | |
|
712 Misty Ave, Mc Farland, CA 93250-1670 | |
| (661) 229-3776 | |
| Not Available |
| Full Name | Dr Frederick Yosef Machado |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 712 Misty Ave, Mc Farland, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831217397 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY23265 (California) | Primary |
| Entity Name | Omni Family Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700891660 PECOS PAC ID: 9234176363 Enrollment ID: O20050411000986 |
News Archive
Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.
A recent study aimed to determine the efficacy of pronation maneuvers by the ICU physiotherapy team when used on critically ill COVID-19 patients.
Speaking on Saturday at the African Union Summit, UNAIDS Executive Director Michel Sidibe said huge advances in HIV treatment and prevention have been made over the past decade in Africa, "but these gains 'are not sustainable,' ... because they are heavily dependent on foreign aid," the Zimbabwean reports.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frederick Yosef Machado, PSYD 712 Misty Ave, Mc Farland, CA 93250-1670 Ph: (661) 229-3776 | Dr Frederick Yosef Machado, PSYD 712 Misty Ave, Mc Farland, CA 93250-1670 Ph: (661) 229-3776 |
News Archive
Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.
A recent study aimed to determine the efficacy of pronation maneuvers by the ICU physiotherapy team when used on critically ill COVID-19 patients.
Speaking on Saturday at the African Union Summit, UNAIDS Executive Director Michel Sidibe said huge advances in HIV treatment and prevention have been made over the past decade in Africa, "but these gains 'are not sustainable,' ... because they are heavily dependent on foreign aid," the Zimbabwean reports.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
› Verified 6 days ago